{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T15:04:18Z","timestamp":1775228658318,"version":"3.50.1"},"reference-count":0,"publisher":"Therapeutic Guidelines Limited","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aust Prescr"],"DOI":"10.18773\/austprescr.2021.066","type":"journal-article","created":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T19:45:41Z","timestamp":1638906341000},"page":"34-35","source":"Crossref","is-referenced-by-count":0,"title":["New drug: Zanubrutinib for mantle cell lymphoma, Waldenstr\u00f6m's macroglobulinaemia"],"prefix":"10.18773","volume":"45","member":"39051","published-online":{"date-parts":[[2021,12,10]]},"container-title":["Australian Prescriber"],"original-title":[],"link":[{"URL":"https:\/\/australianprescriber.tg.org.au\/articles\/zanubrutinib-for-mantle-cell-lymphoma-waldenstroms-macroglobulinaemia.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T14:18:30Z","timestamp":1775225910000},"score":1,"resource":{"primary":{"URL":"https:\/\/australianprescriber.tg.org.au\/articles\/zanubrutinib-for-mantle-cell-lymphoma-waldenstroms-macroglobulinaemia.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,10]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,2,1]]}},"URL":"https:\/\/doi.org\/10.18773\/austprescr.2021.066","relation":{},"ISSN":["1839-3942"],"issn-type":[{"value":"1839-3942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,10]]}}}